Safety and Efficacy of a New High-Dose Chemotherapy (HDC) Regimen of Panobinostat (pano), Gemcitabine (gem), Busulfan (bu) and Melphalan (mel) (pano/gbm) with Autologous Stem Cell Transplant (ASCT) for Patients (pts) with High-Risk (HR) or Refractory/Relapsed (R/R) Myeloma (MM) – Matched Pair Comparisons with a Concurrent Control Cohort